By Order of the Federal Maritime Commission.

Dated: December 28, 1998.

#### Joseph C. Polking,

Secretary.

[FR Doc. 98–34723 Filed 12–30–98; 8:45 am] BILLING CODE 6730–01–M

#### FEDERAL RESERVE SYSTEM

### Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 28, 1999.

A. Federal Reserve Bank of Chicago (Philip Jackson, Applications Officer) 230 South LaSalle Street, Chicago, Illinois 60690-1413:

- 1. First Business Bancshares, Inc., Madison, Wisconsin; to acquire 50.05 percent of the voting shares of Fox River Valley Bancorp, Inc., Appleton, Wisconsin, and thereby indirectly acquire First Business Bank of Fox River Valley, Appleton, Wisconsin, a de novo bank
- 2. First DuPage Bancorp, Inc., Westmont, Illinois; to become a bank holding company by acquiring 100 percent of the voting shares of First DuPage Bank, Westmont, Illinois.

- 3. Fox River Valley Bancorp, Inc., Appleton, Wisconsin; to become a bank holding company by acquiring 100 percent of the voting shares First Business Bank of Fox River Valley, Appleton, Wisconsin, a de novo bank.
- 4. First Merchants Corporation, Muncie, Indiana; to merge with Jay Financial Corporation, Portland, Indiana, and thereby indirectly acquire First National Bank of Portland, Portland, Indiana.
- 5. Standard Bancshares, Inc., Evergreen Park, Illinois; to acquire 100 percent of the voting shares of Norton Capital Corporation, Morris, Illinois, and thereby indirectly acquire Exchange Bank, Gardner, Illinois.

Board of Governors of the Federal Reserve System, December 28, 1998.

#### Jennifer J. Johnson,

Secretary of the Board.
[FR Doc. 98–34724 Filed 12–30–98; 8:45 am]
BILLING CODE 6210–01–F

### FEDERAL RESERVE SYSTEM

### Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage de novo, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 19, 1999.

A. Federal Reserve Bank of San Francisco (Maria Villanueva, Manager of Analytical Support, Consumer Regulation Group) 101 Market Street, San Francisco, California 94105-1579:

1. Wells Fargo & Company, San Francisco, California; Norwest Mortgage, Inc., Des Moines, Iowa; and Norwest Ventures, LLC, Des Moines, Iowa; to engage de novo through their subsidiary, MidAmerican Home Services Mortgage, LLC, West Des Moines, Iowa, in residential mortgage lending, pursuant to § 225.28(b)(1) of Regulation Y.

Board of Governors of the Federal Reserve System, December 28, 1998.

#### Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 98-34725 Filed 12-30-98; 8:45 am] BILLING CODE 6210-01-F

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Notice of a Meeting of the National Bioethics Advisory Commission (NBAC)

SUMMARY: Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is given of a meeting of the National Bioethics Advisory Commission. The Commission will address (1) research involving human embryonic stem cells and (2) the use of human biological materials in research. Some Commission members may participate by telephone conference. The meeting is open to the public and opportunities for statements by the public will be provided on January 19, 1999 from 11:45 am to 12:15 pm.

Dates/Times, and Location

January 19, 1999, 8:30 am-5:00 pm; The New Hampshire Ballroom, Sheraton City Centre Hotel, 1143 New Hampshire Avenue, NW, Washington, DC.

January 20, 1999, 8:00 am-5:00 pm; Same Location as Above.

SUPPLEMENTARY INFORMATION: The President established the National Bioethics Advisory Commission (NBAC) on October 3, 1995 by Executive Order 12975 as amended. The mission of the NBAC is to advise and make recommendations to the National Science and Technology Council, its Chair, the President, and other entities on bioethical issues arising from the research on human biology and behavior, and from the applications of that research.

#### **Public Participation**

The meeting is open to the public with attendance limited by the

availability of space on a first come, first serve basis. Members of the public who wish to present oral statements should contact Ms. Patricia Norris by telephone, fax machine, or mail as shown below and as soon as possible at least 4 days before the meeting. The Chair will reserve time for presentations by persons requesting to speak and asks that oral statements be limited to five minutes. The order of persons wanting to make a statement will be assigned in the order in which requests are received. Individuals unable to make oral presentations can mail or fax their written comments to the NBAC staff office at least five business days prior to the meeting for distribution to the Commission and inclusion in the public record. The Commission also accepts general comments at its website at bioethics.gov. Persons needing special assistance, such as sign language interpretation or other special accommodations, should contact NBAC staff at the address or telephone number listed below as soon as possible.

FOR FURTHER INFORMATION CONTACT: Ms. Patricia Norris, National Bioethics Advisory Commission, 6100 Executive Boulevard, Suite 5B01, Rockville, Maryland 20892–7508, telephone 301–402–4242, fax number 301–480–6900.

Dated: December 23, 1998.

#### Eric M. Meslin,

Executive Director, National Bioethics Advisory Commission.

[FR Doc. 98–34630 Filed 12–30–98; 8:45 am] BILLING CODE 4160–17–P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

# Ethics Subcommittee of the Advisory Committee to the Director, Centers for Disease Control and Prevention: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following subcommittee meeting.

Name: Ethics Subcommittee of the Advisory Committee to the Director, CDC. Time and date: 9 a.m.-3 p.m., January 21, 1999.

Place: Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Building 16, Room 5126, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 25 people. *Purpose:* This subcommittee will anticipate, identify, and propose solutions to strategic and broad ethical issues facing CDC.

Matters to be discussed: Agenda items will include updates from the Associate Director for Science, Dixie E. Snider, M.D., M.P.H.; a discussion on ethics around mandatory vaccination programs; and developing ethical guidelines for public health practice.

Agenda items are subject to change as priorities dictate.

For Further information: Linda Kay McGowan, Executive Secretary, Advisory Committee to the Director, CDC, 1600 Clifton Road, NE., M/S D–24, Atlanta, Georgia 30333. Telephone 404/639–7080.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: December 23, 1998.

#### Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98-34584 Filed 12-30-98; 8:45 am] BILLING CODE 4163-18-P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

### Clinical Laboratory Improvement Advisory Committee (CLIAC): Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

*Name:* Clinical Laboratory Improvement Advisory Committee (CLIAC).

Time and Date: 8 a.m.-4:30 p.m., February 3, 1999.

Place: CDC, Koger Center, Williams Building, Conference Rooms 1802 and 1805, 2877 Brandywine Road, Atlanta, Georgia 30341

Status: Open to the public, limited only by the space available. The meeting rooms accommodate approximately 85 people.

Purpose: This committee is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the need for, and the nature of, revisions to the standards under which clinical laboratories are regulated; the impact of proposed revisions to the standards; and the modification of the standards to accommodate technological advances.

Matters to be discussed: The agenda will include an update on CLIA implementation; HCFA validation inspections of accredited laboratories; update on research for CLIA

Cytology requirements; and information on HCFA inspections of cytology laboratories.

Agenda items are subject to change as priorities dictate.

For further information contact: John C. Ridderhof, Dr.P.H., Division of Laboratory Systems, Public Health Practice Program Office, CDC, 4770 Buford Highway, NE., Mailstop G–25, Atlanta, Georgia 30341–3724. Telephone 770/488–8076, FAX 770/488–8282.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: December 23, 1998.

#### Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98-34586 Filed 12-30-98; 8:45 am] BILLING CODE 4163-18-P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

### National Center for Environmental Health; Meeting

The National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC) announces the following meeting:

*Name:* A Public Health Response to Asthma.

Times and Dates: 1 p.m.–8 p.m., February 9, 1999; 8:30 a.m.–5 p.m., February 10, 1999; 8:30 a.m.–12 p.m., February 11, 1999.

Place: Sheraton Colony Šquare, 188 14th Street, NE Atlanta, Georgia 30361. Telephone, 404/892–6000.

*Status*: Open to the public, limited only by space available. The meeting space accommodates approximately 200 people.

Purpose: The purpose of this conference is to provide a forum for increasing knowledge regarding asthma prevention and control and an update of current asthma surveillance and intervention activities in State and local health agencies. It will also provide a forum for interaction with colleagues from across the country.

Matters To Be Discussed: Agenda items include a discussion of the epidemiology and cost of asthma; community interventions; legislation; coalitions; and lessons learned from ongoing programs. Concurrent workgroups, round tables, and topic tables will be held to further detailed discussions on asthma related topics.

Agenda items are subject to change as priorities dictate.

For Further Information Contact: Leslie Boss, Ph.D., Air Pollution and Respiratory Health Branch, Division of Environmental